STADOL
LOE ApproachingNDANASALSPRAY, METERED
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STADOL (butorphanol) is a nasal spray metered-dose formulation of a mixed opioid agonist-antagonist approved in 1991 by Bristol Myers Squibb. The mechanism of action involves opioid receptor modulation for pain relief. The exact indications are not specified in available data, but nasal butorphanol is typically used for moderate pain management and migraine headache treatment.
LOE Approaching
Product is in late-stage lifecycle with low competitive pressure (30/100), suggesting a mature brand team focused on margin preservation rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STADOL currently has zero linked job openings, reflecting its mature, stable commercial status with minimal expansion plans. Career opportunities on this product are limited to cost management and market retention roles rather than growth-oriented positions.
Brand ManagerField Sales Representative
Worked on STADOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.